Nonlipid biomarkers fail at predicting major CV events

New research seems to confirm what has already been suspected about nonlipid biomarkers: They may be good at predicting coronary heart disease, but they are not so good at predicting the risk for major cardiovascular events. John Kastelein of the Academic Medical Center in Amsterdam, along with his colleagues, measured levels of standard lipids and 18 nonlipid biomarkers in more than 1,500 CHD patients. They also assessed the incidence of major CV events. Almost none of the nonlipid biomarkers were able to predict the major cardiovascular events. Story

Suggested Articles

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.

Illumina will drop $8 billion to reacquire its former spinout, which after nearly five years is nearing completion of its cancer-seeking blood test.

The CE Mark for the system’s fourth iteration follows a July 2019 approval from the FDA.